share_log

雲頂新耀-B：自願公告 最新業務情況

EVEREST MED-B: VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

香港交易所 ·  Jan 21 17:56
Summary by Moomoo AI
雲頂新耀-B（云顶新耀-B）宣佈，根據初步評估，公司預計2023年全年總收入將達到人民幣1.24億元至1.26億元，較2022年的人民幣1,280萬元大幅增長。這一增長主要得益於Xerava®（依拉環素）和Nefecon®在中國及澳門的成功上市。公司指出，這些數據基於未經審核的管理帳目，並可能因審計過程中的不確定因素而有所調整。公司將於2024年3月發布經審核的年度業績報告。
雲頂新耀-B（云顶新耀-B）宣佈，根據初步評估，公司預計2023年全年總收入將達到人民幣1.24億元至1.26億元，較2022年的人民幣1,280萬元大幅增長。這一增長主要得益於Xerava®（依拉環素）和Nefecon®在中國及澳門的成功上市。公司指出，這些數據基於未經審核的管理帳目，並可能因審計過程中的不確定因素而有所調整。公司將於2024年3月發布經審核的年度業績報告。
Genting Xinhu-B announced that, based on preliminary estimates, the company expects full-year revenue of RMB1.24 billion to $1.26 billion in 2023, a significant increase from RMB1,280 million in 2022. This growth has been driven primarily by the successful market listings of Xerava® (Erylanosine) and Nefecon® in China and Macau. The Company notes that these data are based on unaudited management accounts and may be adjusted due to uncertainties during the audit process. The company will release an audited annual results report in March 2024.
Genting Xinhu-B announced that, based on preliminary estimates, the company expects full-year revenue of RMB1.24 billion to $1.26 billion in 2023, a significant increase from RMB1,280 million in 2022. This growth has been driven primarily by the successful market listings of Xerava® (Erylanosine) and Nefecon® in China and Macau. The Company notes that these data are based on unaudited management accounts and may be adjusted due to uncertainties during the audit process. The company will release an audited annual results report in March 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more